GGrantIndex
← Leaderboards

Zylo Therapeutics, Inc.

Greenville, SC

Compare ↔
$3,387,421
Total funding
6
Grants

Funding over time

peak $1.6M · FY2019–25
$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$3,387,421 · 6

By mechanism

R44$1,705,226 · 1
R41$1,682,195 · 5

Investigators at Zylo Therapeutics, Inc.

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

1Waleed M Abuzeid$150,0001 gr

Emerging Leaders

6–10 yrs in

1Andrew R Draganski$2,678,0476 gr

All-Time

Most funded here, all years

1Andrew R Draganski$2,678,0476 gr2Waleed M Abuzeid$150,0001 gr

Largest grants

Development of microparticle-based topical treatments for treating erectile dysfunction in patients refractory to oral PDE5 inhibitors$1,008,058
R44 · FY2022 · DK
Development of microparticle-based topical treatments for treating erectile dysfunction in patients refractory to oral PDE5 inhibitors$697,168
R44 · FY2021 · DK
Development and optimization of a nitric oxide releasing microparticle formulation for the topical treatment of chronic rhinosinusitis$300,000
R41 · FY2025 · AI
Development and optimization of a nitric oxide releasing microparticle-basedtopical treatment for onychomycosis$300,000
R41 · FY2022 · AI
Development and optimization of a nitric oxide releasing microparticle-basedtopical treatment for onychomycosis$300,000
R41 · FY2023 · AI
Optimization of a nanoparticle-based topical PDE5i formulation for treatment of erectile dysfunction$263,446
R41 · FY2022 · DK
Optimization of microparticle-based topical treatments for treating erectile dysfunction in patients refractory to oral PDE5 inhibitors$225,000
R41 · FY2019 · DK
Development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus.$147,861
R41 · FY2023 · AR
Development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus.$145,888
R41 · FY2024 · AR